Edition:
United Kingdom

Collegium Pharmaceutical Inc (COLL.OQ)

COLL.OQ on NASDAQ Stock Exchange Global Select Market

12.05USD
14 Jun 2019
Change (% chg)

$-0.15 (-1.23%)
Prev Close
$12.20
Open
$12.13
Day's High
$12.33
Day's Low
$12.03
Volume
69,029
Avg. Vol
129,773
52-wk High
$28.87
52-wk Low
$10.55

Latest Key Developments (Source: Significant Developments)

Collegium Reports Q1 Loss Per Share $0.29
Wednesday, 8 May 2019 

May 8 (Reuters) - Collegium Pharmaceutical Inc ::COLLEGIUM REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.29.Q1 EARNINGS PER SHARE ESTIMATE $-0.24 -- REFINITIV IBES DATA.QTRLY TOTAL NET PRODUCT REVENUES WERE $74.5 MILLION COMPARED TO $63.7 MILLION.  Full Article

Collegium Reports Fourth-Quarter And Full-Year 2018 Financial Results
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - Collegium Pharmaceutical Inc ::COLLEGIUM REPORTS FOURTH-QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS.Q4 EARNINGS PER SHARE $0.27.Q4 EARNINGS PER SHARE ESTIMATE $-0.35 -- REFINITIV IBES DATA.Q4 REVENUE $73.4 MILLION VERSUS REFINITIV IBES ESTIMATE OF $73.9 MILLION.  Full Article

Collegium Says Nucynta Franchise Revenue Expected In Range Of $200 Mln To $210 Mln In 2019
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Collegium Pharmaceutical Inc ::COLLEGIUM PROVIDES FULL-YEAR 2019 FINANCIAL GUIDANCE.COLLEGIUM PHARMACEUTICAL INC - XTAMPZA ER REVENUE EXPECTED IN RANGE OF $95 MILLION TO $105 MILLION IN 2019.COLLEGIUM PHARMACEUTICAL INC - NUCYNTA FRANCHISE REVENUE EXPECTED IN RANGE OF $200 MILLION TO $210 MILLION IN 2019.COLLEGIUM PHARMACEUTICAL INC - TOTAL OPERATING EXPENSES EXPECTED IN RANGE OF $125 MILLION TO $135 MILLION IN 2019.  Full Article

Collegium Pharmaceutical Q2 Loss Per Share $0.40
Wednesday, 8 Aug 2018 

Collegium Pharmaceutical Inc ::COLLEGIUM REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.40.Q2 REVENUE $73.1 MILLION VERSUS I/B/E/S VIEW $72.2 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.42 -- THOMSON REUTERS I/B/E/S.EXPECTS TO FINISH YEAR WITH AT LEAST $135.0 MILLION IN CASH.  Full Article

Janus Henderson Group Reports 10.1 Pct Passive Stake In Collegium Pharmaceutical
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Collegium Pharmaceutical Inc ::JANUS HENDERSON GROUP PLC REPORTS 10.1 PERCENT PASSIVE STAKE IN COLLEGIUM PHARMACEUTICAL AS OF DEC 31, 2017 - SEC FILING.  Full Article

BioDelivery Sciences Reacquires Onsolis From Collegium Pharmaceutical
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES REACQUIRES ONSOLIS® FROM COLLEGIUM PHARMACEUTICAL.BIODELIVERY SCIENCES - GOT 90-DAY NOTICE FROM COLLEGIUM REGARDING TERMINATION OF LICENSE AND DEVELOPMENT AGREEMENT FOR ONSOLIS.BIODELIVERY SCIENCES INTERNATIONAL - TERMINATION OF AGREEMENT WILL BE EFFECTIVE ON MARCH 8, 2018.BIODELIVERY SCIENCES - COLLEGIUM TO TERMINATE LICENSE DUE TO ITS AGREEMENT TO COMMERCIALIZE NUCYNTA IMMEDIATE RELEASE, NUCYNTA ER.BIODELIVERY SCIENCES - "WE WILL BE ASSESSING OPTIONS FOR COMMERCIALIZING ONSOLIS".BIODELIVERY SCIENCES - DO NOT CURRENTLY BELIEVE RETURN OF ONSOLIS TO US WILL HAVE MATERIAL IMPACT ON BUSINESS.  Full Article

Depomed Announces Nucynta® Commercialization Agreement With Collegium Pharmaceutical
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Depomed Inc ::DEPOMED ANNOUNCES NUCYNTA® COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL.DEPOMED INC - RELOCATION OF COMPANY HEADQUARTERS MID-2018.DEPOMED INC - TRANSACTION IS IMMEDIATELY ACCRETIVE AND IMPROVES 2018 EBITDA OUTLOOK.DEPOMED - PLANS TO RELOCATE ITS CORPORATE HEADQUARTERS FROM NEWARK, SOMETIME IN MID-2018 & IS CURRENTLY EVALUATING POTENTIAL MIDWEST & EAST COAST LOCATIONS.DEPOMED INC - COMPANY WILL REDUCE ITS STAFF BY 40% TO APPROXIMATELY 70 EMPLOYEES AND HEADQUARTERS OFFICE SPACE REQUIREMENT BY 50%.DEPOMED INC - EXPECTS TO SAVE APPROXIMATELY $10 MILLION ANNUALLY AS A RESULT OF HEADQUARTERS RESTRUCTURING AND RELOCATION.DEPOMED INC - WILL ELIMINATE ITS PAIN SALESFORCE AND CEASE ALL BRAND SPENDING ON NUCYNTA.DEPOMED INC - BY ELIMINATING ITS PAIN SALESFORCE AND CEASE ALL BRAND SPENDING CO TO REDUCE SG&A EXPENSES BY ABOUT $70 MILLION ON AN ANNUAL BASIS.DEPOMED INC - UNDER TERMS OF AGREEMENT, COLLEGIUM WILL COMMERCIALIZE BOTH NUCYNTA EXTENDED RELEASE AND NUCYNTA IMMEDIATE RELEASE.DEPOMED INC - DEPOMED WILL RECEIVE A ROYALTY RATE ON ALL NUCYNTA REVENUES BASED ON CERTAIN NET SALES THRESHOLDS.  Full Article

Collegium To License Rights To Commercialize Nucynta Franchise
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Collegium Pharmaceutical Inc ::COLLEGIUM TO LICENSE RIGHTS TO COMMERCIALIZE NUCYNTA FRANCHISE.COLLEGIUM PHARMACEUTICAL INC - DEAL IS IMMEDIATELY ACCRETIVE.COLLEGIUM PHARMACEUTICAL INC - ENTERED INTO A DEFINITIVE COMMERCIALIZATION AGREEMENT WITH DEPOMED.COLLEGIUM PHARMACEUTICAL - FOR FIRST FOUR YEARS OF AGREEMENT, COLLEGIUM WILL PAY A MINIMUM ANNUAL LICENSE FEE OF $135.0 MILLION PAID QUARTERLY IN ARREARS.COLLEGIUM PHARMACEUTICAL - FOR FIRST FOUR YEARS OF AGREEMENT, COLLEGIUM WILL ALSO PAY DOUBLE-DIGIT ROYALTIES ON NET SALES ABOVE $233.0 MILLION PER YEAR.COLLEGIUM PHARMACEUTICAL - AFTER 12 MONTHS, CO MAY TERMINATE AGREEMENT WITH TWELVE MONTHS' NOTICE AND PAYMENT OF A $25.0 MILLION TERMINATION FEE.COLLEGIUM PHARMACEUTICAL INC - AFTER FOUR YEARS OF AGREEMENT, COLLEGIUM WILL PAY DOUBLE-DIGIT ROYALTIES ON ALL NET SALES.COLLEGIUM PHARMACEUTICAL INC - TRANSACTION HAS BEEN APPROVED BY COLLEGIUM'S AND DEPOMED'S BOARD OF DIRECTORS.COLLEGIUM PHARMACEUTICAL INC - EXPECTS TO SUPPORT NUCYNTA FRANCHISE WITH ITS EXISTING RETAIL AND HOSPITAL FIELD FORCES.COLLEGIUM PHARMACEUTICAL INC - WILL RECEIVE AN EXCLUSIVE SUBLICENSE TO COMMERCIALIZE NUCYNTA AND NUCYNTA ER IN UNITED STATES.  Full Article

Collegium reports third quarter loss of $0.45 per share
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Collegium Pharmaceutical Inc :Collegium reports third quarter financial results and provides corporate update.Q3 loss per share $0.45.Q3 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.  Full Article

Collegium receives FDA approval for sNDA for Xtampza® ER
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Collegium Pharmaceutical Inc :Collegium receives FDA approval for sNDA for Xtampza® ER.  Full Article